News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Prafulla Girase, MS

Articles by Prafulla Girase, MS

Economic Impact of Extended-release Tolterodine versus Immediate-and Extended-release Oxybutynin Among Commercially Insured Persons With Overactive Bladder

BySujata Varadharajan, MS,Zhanna Jumadilova, MD, MBA,Prafulla Girase, MS,Daniel A. Ollendorf, MPH

July 15th 2005

Latest Updated Articles

Economic Impact of Extended-release Tolterodine versus Immediate-and Extended-release Oxybutynin Among Commercially Insured Persons With Overactive Bladder
Published: July 15th 2005 | Updated:

Trending on AJMC

Newly Unveiled ACA Premiums Show 26% Average Increase Before Subsidy Expiration

Empagliflozin Reduces HF Risk After AMI in Patients With or Without Diabetes, CKD

FDA Guidance to Remove One of the Largest Barriers to Biosimilar Development

Balancing Efficacy and Safety in BTKi Therapy

Measles Outbreaks Cause Financial, Public Health Burden in US

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

© 2025 MJH Life Sciences^®

All rights reserved.